Literature DB >> 24375511

Executive functions in premanifest Huntington's disease.

S Christine You1, Michael D Geschwind, Sharon J Sha, Alexandra Apple, Gabriella Satris, Kristie A Wood, Erica T Johnson, Jonathan Gooblar, Jeanne S Feuerstein, Steven Finkbeiner, Gail A Kang, Bruce L Miller, Christopher P Hess, Joel H Kramer, Katherine L Possin.   

Abstract

BACKGROUND: We investigated the viability of psychometrically robust executive function measures as markers for premanifest Huntington's disease (HD).
METHODS: Fifteen premanifest HD subjects and 42 controls were compared on the NIH EXAMINER executive function battery. This battery yields an overall executive composite score, plus working memory, cognitive control, and fluency scores that are measured on psychometrically matched scales. The scores were correlated with two disease markers, disease burden and striatal volumes, in the premanifest HD subjects.
RESULTS: The premanifest HD subjects scored significantly lower on the working memory score. The executive composite positively correlated with striatal volumes, and the working memory score negatively correlated with disease burden. The cognitive control and fluency scores did not differ between the groups or correlate significantly with the disease markers.
CONCLUSIONS: The NIH EXAMINER executive composite and working memory scores are sensitive markers of cognitive dysfunction, striatal volume, and disease burden in premanifest HD.
© 2013 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's disease; disease burden; executive function; striatal volume; working memory

Mesh:

Year:  2013        PMID: 24375511      PMCID: PMC4029327          DOI: 10.1002/mds.25762

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  38 in total

1.  A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.

Authors:  Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

2.  A power primer.

Authors:  J Cohen
Journal:  Psychol Bull       Date:  1992-07       Impact factor: 17.737

3.  Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.

Authors:  Alexander Peinemann; Sabine Schuller; Córina Pohl; Thomas Jahn; Adolf Weindl; Jan Kassubek
Journal:  J Neurol Sci       Date:  2005-09-26       Impact factor: 3.181

4.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

5.  Functional magnetic resonance imaging of working memory in Huntington's disease: cross-sectional data from the IMAGE-HD study.

Authors:  Nellie Georgiou-Karistianis; Julie C Stout; Juan F Domínguez D; Sarah P Carron; Ayaka Ando; Andrew Churchyard; Phyllis Chua; India Bohanna; Alicia R Dymowski; Govinda Poudel; Gary F Egan
Journal:  Hum Brain Mapp       Date:  2013-08-02       Impact factor: 5.038

6.  Ecological validity and neuroanatomical correlates of the NIH EXAMINER executive composite score.

Authors:  Katherine L Possin; Amanda K LaMarre; Kristie A Wood; Dan M Mungas; Joel H Kramer
Journal:  J Int Neuropsychol Soc       Date:  2013-06-14       Impact factor: 2.892

7.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

Review 8.  Anosognosia: clinical and ethical considerations.

Authors:  George P Prigatano
Journal:  Curr Opin Neurol       Date:  2009-12       Impact factor: 5.710

9.  Evidence for specific cognitive deficits in preclinical Huntington's disease.

Authors:  A D Lawrence; J R Hodges; A E Rosser; A Kershaw; C ffrench-Constant; D C Rubinsztein; T W Robbins; B J Sahakian
Journal:  Brain       Date:  1998-07       Impact factor: 13.501

10.  Cognitive domains that predict time to diagnosis in prodromal Huntington disease.

Authors:  Deborah Lynn Harrington; Megan M Smith; Ying Zhang; Noelle E Carlozzi; Jane S Paulsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-03-26       Impact factor: 10.154

View more
  21 in total

1.  Sensitive measures of executive dysfunction in non-demented Parkinson's disease.

Authors:  Nicholas T Bott; Erica T Johnson; Norbert Schuff; Nicholas Galifianakis; Trishna Subas; Jessica Pollock; Peter Pressman; Joel H Kramer; Katherine L Possin
Journal:  Parkinsonism Relat Disord       Date:  2014-10-15       Impact factor: 4.891

2.  Egocentric and allocentric visuospatial working memory in premotor Huntington's disease: A double dissociation with caudate and hippocampal volumes.

Authors:  Katherine L Possin; Hosung Kim; Michael D Geschwind; Tacie Moskowitz; Erica T Johnson; Sharon J Sha; Alexandra Apple; Duan Xu; Bruce L Miller; Steven Finkbeiner; Christopher P Hess; Joel H Kramer
Journal:  Neuropsychologia       Date:  2017-04-17       Impact factor: 3.139

3.  Surface-based morphometry reveals caudate subnuclear structural damage in patients with premotor Huntington disease.

Authors:  Hosung Kim; Ji-Hoon Kim; Katherine L Possin; Joseph Winer; Michael D Geschwind; Duan Xu; Christopher P Hess
Journal:  Brain Imaging Behav       Date:  2017-10       Impact factor: 3.978

4.  NIH Toolbox Cognition Battery (NIHTB-CB): list sorting test to measure working memory.

Authors:  David S Tulsky; Noelle Carlozzi; Nancy D Chiaravalloti; Jennifer L Beaumont; Pamela A Kisala; Dan Mungas; Kevin Conway; Richard Gershon
Journal:  J Int Neuropsychol Soc       Date:  2014-06-24       Impact factor: 2.892

5.  Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.

Authors:  Verónica Brito; Albert Giralt; Lilian Enriquez-Barreto; Mar Puigdellívol; Nuria Suelves; Alfonsa Zamora-Moratalla; Jesús J Ballesteros; Eduardo D Martín; Nuria Dominguez-Iturza; Miguel Morales; Jordi Alberch; Sílvia Ginés
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

6.  Interaction without intent: the shape of the social world in Huntington's disease.

Authors:  Clare M Eddy; Hugh E Rickards
Journal:  Soc Cogn Affect Neurosci       Date:  2015-02-12       Impact factor: 3.436

7.  Quantitative 7T phase imaging in premanifest Huntington disease.

Authors:  A C Apple; K L Possin; G Satris; E Johnson; J M Lupo; A Jakary; K Wong; D A C Kelley; G A Kang; S J Sha; J H Kramer; M D Geschwind; S J Nelson; C P Hess
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

8.  Central Cognitive Processing Speed Is an Early Marker of Huntington's Disease Onset.

Authors:  Jody Corey-Bloom; McKenna E Williams; Ilex Beltran-Najera; Andrea I Mustafa; Chase M Snell; Jordan Castleton; Haileigh Smith; Brenton Wright; Paul E Gilbert
Journal:  Mov Disord Clin Pract       Date:  2020-12-28

9.  Digital Cognitive Assessments for Dementia: Digital assessments may enhance the efficiency of evaluations in neurology and other clinics.

Authors:  Adam M Staffaroni; Elena Tsoy; Jack Taylor; Adam L Boxer; Katherine L Possin
Journal:  Pract Neurol (Fort Wash Pa)       Date:  2020 Nov-Dec

10.  Varenicline improves motor and cognitive symptoms in early Huntington's disease.

Authors:  Ailsa L McGregor; Jo Dysart; Malcolm D Tingle; Bruce R Russell; Rob R Kydd; Gregory Finucane
Journal:  Neuropsychiatr Dis Treat       Date:  2016-09-19       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.